3/19
09:27 pm
cogt
Fidelity Small Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
Medium
Report
Fidelity Small Cap Growth Fund Q4 2025 Commentary [Seeking Alpha]
3/17
08:43 am
cogt
Cogent Biosciences (COGT) had its "outperform" rating reaffirmed by Wedbush. They now have a $55.00 price target on the stock.
Low
Report
Cogent Biosciences (COGT) had its "outperform" rating reaffirmed by Wedbush. They now have a $55.00 price target on the stock.
3/16
10:58 am
cogt
Cogent Biosciences (COGT) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
Low
Report
Cogent Biosciences (COGT) is now covered by Jefferies Financial Group Inc.. They set a "buy" rating on the stock.
3/16
08:34 am
cogt
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) [Yahoo! Finance]
Medium
Report
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM) [Yahoo! Finance]
3/16
08:00 am
cogt
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
Medium
Report
Cogent Biosciences Announces FDA Acceptance of New Drug Application for Bezuclastinib in Patients with NonAdvanced Systemic Mastocytosis (NonAdvSM)
3/14
02:44 pm
cogt
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? [Yahoo! Finance]
Medium
Report
Is Cogent Biosciences (COGT) One of the Best Multibagger Stocks to Buy According to Billionaires? [Yahoo! Finance]
3/14
12:32 pm
cogt
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches [Yahoo! Finance]
Medium
Report
Cogent Biosciences Touts Bezuclastinib Pivotal Wins, Eyes Up to Three FDA Filings and U.S. Launches [Yahoo! Finance]
3/3
09:41 pm
cogt
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility [Yahoo! Finance]
Low
Report
A Look At Cogent Biosciences (COGT) Valuation After Recent Share Price Volatility [Yahoo! Finance]
3/3
07:03 pm
cogt
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]
Low
Report
Bezuclastinib SUMMIT Data Reframe Cogent Biosciences Mastocytosis Opportunity [Yahoo! Finance]
3/2
03:12 am
cogt
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval [Yahoo! Finance]
Low
Report
Cogent Biosciences Inc. (COGT) Set for Bezuclastinib Launch, Awaiting FDA Approval [Yahoo! Finance]
2/28
10:13 am
cogt
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting [Yahoo! Finance]
Low
Report
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting [Yahoo! Finance]
2/28
09:45 am
cogt
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
Low
Report
Cogent Biosciences Highlights Additional Data with Six Bezuclastinib Posters from SUMMIT Trial at 2026 AAAAI Annual Meeting
2/27
04:15 pm
cogt
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval [Yahoo! Finance]
Low
Report
Analyst Bullish on Cogent (COGT) Amid Expected Drug Approval [Yahoo! Finance]
2/19
11:11 am
cogt
Cogent Biosciences (NASDAQ:COGT) was given a new $35.00 price target on by analysts at Robert W. Baird.
Low
Report
Cogent Biosciences (NASDAQ:COGT) was given a new $35.00 price target on by analysts at Robert W. Baird.
2/18
07:18 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "overweight" rating reaffirmed by analysts at Piper Sandler.
2/17
08:00 am
cogt
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
Medium
Report
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2025 Financial Results
2/10
08:00 am
cogt
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
Low
Report
Cogent Biosciences Announces Multiple SUMMIT Posters at the 2026 AAAAI Annual Meeting
2/2
06:20 am
cogt
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]
Medium
Report
Cogent Biosciences FDA Milestones Put Bezuclastinib And Valuation In Focus [Yahoo! Finance]
2/2
04:32 am
cogt
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]
Medium
Report
Cogent Biosciences (COGT) Advances Bezuclastinib-Sunitinib Combination With Breakthrough Therapy Designation (BTD) [Yahoo! Finance]
2/1
02:28 am
cogt
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]
Medium
Report
Large Biotech Fund Sells Shares of Cogent Biosciences for Over $120M [Yahoo! Finance]
1/31
01:33 am
cogt
Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at
Wall Stre
Medium
Report
Cogent Biosciences (NASDAQ:COGT) was downgraded by analysts at
Wall Stre
1/27
08:33 am
cogt
Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]
Low
Report
Cogent Biosciences announcse U.S. BTD for bezuclastinib [Yahoo! Finance]
1/26
08:00 am
cogt
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
Low
Report
Cogent Biosciences Announces Breakthrough Therapy Designation for Bezuclastinib in Combination with Sunitinib for Patients with Gastrointestinal Stromal Tumors (GIST)
1/21
11:22 am
cogt
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
Low
Report
Cogent Biosciences (COGT) Is Up 13.1% After FDA RTOR Nod For Bezuclastinib Combo - Has The Bull Case Changed? [Yahoo! Finance]
1/21
09:05 am
cogt
Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.
Low
Report
Cogent Biosciences (NASDAQ:COGT) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $55.00 price target on the stock.